# Tofacitinib

## Xeljanz 5mg

| 藥物代碼 | OXELJ |
| :--- | :--- |
| 適應症 | Rheumatoid arthritis: Treatment of moderately- to severely-active rheumatoid arthritis \(as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs\) in adults who have had an inadequate response to, or are intolerant of, methotrexate. |
| 副作用 | &gt;10% Infection: Infection \(20% to 22%\)1% to 10%:Cardiovascular: Hypertension \(2%\)Central nervous system: Headache \(4%\)Gastrointestinal: Diarrhea \(4%\)Genitourinary: Urinary tract infection \(2%\)Hepatic: Increased serum ALT \(&gt;3 x upper limit of normal; 1%\)Infection: Serious infection \(2% to 3%\)Renal: Increased serum creatinine \(&lt;2%\)Respiratory: Upper respiratory tract infection \(5%\), nasopharyngitis \(4%\)&lt;1% \(Limited to important or life-threatening\): Abdominal pain, anemia, BK virus, cellulitis, cryptococcosis, cytomegalovirus disease, decreased heart rate, dehydration, dyspepsia, erythema, esophageal candidiasis, gastritis, hepatotoxicity, herpes zoster, increased creatine kinase, increased serum AST, interstitial pulmonary disease, liver steatosis, lymphocytopenia, malignant neoplasm, musculoskeletal pain, neutropenia, paresthesia, peripheral edema, pneumocystosis, pneumonia, prolongation P-R interval on ECG, pruritus, rhabdomyolysis, sinus congestion, skin carcinoma, skin rash, tendonitis, tuberculosis |
| 禁忌 | Hypersensitivity to tofacitinib or any component of the formulation |
| 藥物保存方式 | 室溫 |
| 用法用量 | Dosing: Adult Rheumatoid arthritis \(monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs \(DMARDs\): Oral: 5 mg twice daily. |
| 肝功能異常 | 需 調 整 劑 量  Moderate impairment: Reduce dose to 5 mg \(immediate release\) once daily. Severe impairment: Use is not recommended \(has not been studied in patients with severe hepatic impairment or in patients with hepatitis B or hepatitis C viruses\). |
| 腎功能異常 | 需 調 整 劑 量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest low risk |
| 附帶說明 | PREGNANCY RECOMMENDATION: Contraindicated if Combined with Methotrexate |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | BREASTFEEDING RECOMMENDATION: Contraindicated if Combined with Methotrexate |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

